Merit Medical Systems Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported):
(Exact name of registrant as specified in its charter)
| | |||
(State or other jurisdiction of | (Commission | (I.R.S. Employer | ||
incorporation or organization) | File Number) | Identification No.) |
| ||
(Address of principal executive offices) | (Zip Code) |
(
(Registrant's telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | | Trading Symbol(s) | | Name of each exchange on which registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01 Regulation FD Disclosure
The information contained in Item 7.01 of this Current Report on Form 8-K is being furnished by Merit Medical Systems, Inc. (“Merit”) to provide historical revenue information disaggregated by its new foundational and therapeutic product categories for the years ended December 31, 2025, 2024, 2023, and 2022, as well as quarterly revenue information for each of the three-month periods ended March 31, 2024 to December 31, 2025. Merit is providing this historical revenue information for the purpose of aiding period-over-period comparisons for the years and three-month periods indicated. The historical revenue information does not constitute a revision or restatement of Merit’s previously reported consolidated financial statements.
Merit’s revenue under the new product categories for the years ended December 31, 2025, 2024, 2023 and 2022, respectively, was as follows (unaudited, in thousands):
Year Ended December 31, | ||||||||||||
| 2025 | | 2024 | | 2023 | | 2022 | |||||
Foundational | $ | 1,028,540 | $ | 964,100 | $ | 926,253 | $ | 862,375 | ||||
Therapeutic | 487,366 |
| 392,414 |
| 331,113 |
| 288,606 | |||||
Total | $ | 1,515,906 | $ | 1,356,514 | $ | 1,257,366 | $ | 1,150,981 | ||||
Merit’s revenue under the new product categories for the three-month periods ended March 31, June 30, September 30, and December 31, 2025, compared to the corresponding periods of 2024, was as follows (unaudited, in thousands):
Three-Month Period Ended | ||||||||||||
2025 | | March 31 | | June 30 | | September 30 | | December 31 | ||||
Foundational | $ | 240,382 | $ | 262,382 | $ | 260,906 | $ | 264,870 | ||||
Therapeutic | 114,969 |
| 120,080 |
| 123,251 |
| 129,066 | |||||
Total | $ | 355,351 | $ | 382,462 | $ | 384,157 | $ | 393,936 | ||||
Three-Month Period Ended | ||||||||||||
2024 | | March 31 | | June 30 | | September 30 | | December 31 | ||||
Foundational | $ | 232,930 | $ | 245,404 | $ | 240,742 | $ | 245,024 | ||||
Therapeutic | 90,578 |
| 92,599 |
| 99,103 |
| 110,134 | |||||
Total | $ | 323,508 | $ | 338,003 | $ | 339,845 | $ | 355,158 | ||||
2
Merit is providing historical revenue information under each product category by product platform for the years ended December 31, 2025, 2024, 2023 and 2022. Such supplemental information is presented for the purpose of providing additional details regarding Merit’s current revenue categories. Merit does not intend to provide revenue information disaggregated by product platform on a recurring basis in future periods.
Merit’s revenue by product platform for the years ended December 31, 2025, 2024, 2023 and 2022, respectively, was as follows (unaudited, in thousands):
Year Ended December 31, | ||||||||||||
| 2025 | | 2024 | | 2023 | | 2022 | |||||
Foundational | ||||||||||||
Access | $ | 588,542 | $ | 538,272 | $ | 527,440 | $ | 498,375 | ||||
OEM | 167,086 | 165,420 | 150,480 | 135,066 | ||||||||
Procedural Solutions | 124,717 | 117,198 | 114,233 | 116,763 | ||||||||
Vascular Intervention | 139,997 | 132,284 | 119,883 | 102,663 | ||||||||
Other | 8,198 | 10,926 | 14,217 | 9,508 | ||||||||
Total Foundational | 1,028,540 | 964,100 | 926,253 | 862,375 | ||||||||
Therapeutic |
| |||||||||||
Cardiac Therapies | 93,357 | 49,436 | 36,415 | 33,632 | ||||||||
Endoscopy | 72,481 | 54,415 | 37,019 | 31,912 | ||||||||
OEM |
| 40,464 |
| 39,886 |
| 42,681 | 38,079 | |||||
Oncology | 96,805 | 86,940 | 77,761 | 67,406 | ||||||||
Renal Therapies | 52,802 | 48,980 | 36,547 | 21,826 | ||||||||
Vascular Intervention | 131,457 | 112,757 | 100,690 | 95,751 | ||||||||
Total Therapeutic | 487,366 | 392,414 | 331,113 | 288,606 | ||||||||
Total | $ | 1,515,906 | $ | 1,356,514 | $ | 1,257,366 | $ | 1,150,981 | ||||
The information contained in this Item 7.01 of this Current Report is furnished pursuant to General Instruction B.2. of Form 8-K and shall not be deemed to be “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing made by Merit under the Securities Act of 1933, as amended (the “Securities Act”), or the Securities Exchange Act of 1934, as amended (the “Exchange Act”).
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
EXHIBIT NUMBER |
| DESCRIPTION |
104 | The cover page from this Current Report on Form 8-K, formatted in Inline XBRL |
3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
MERIT MEDICAL SYSTEMS, INC. | ||
Date: April 13, 2026 | By: | /s/ Brian G. Lloyd |
Brian G. Lloyd | ||
Chief Legal Officer and Corporate Secretary | ||
4